IAVI

Media & Resources

Fact sheets & publications

The following is a selection of recent fact sheets and policy guidance documents produced by IAVI in partnership with key stakeholders.

Download IAVI and partner publications funder acknowledgments

About IAVI

IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

The world needs an HIV vaccine

The only way to end HIV/AIDS as a public health problem of global importance is with a vaccine. IAVI remains committed to developing a safe, effective, globally useful one.

The urgent need for a TB vaccine

A vaccine is necessary to end the TB epidemic. IAVI and partners continue to make strides to reach this goal.

Emerging infectious diseases vaccines

IAVI is applying its vaccine development expertise and working with a group of expert international partners to develop vaccines to prevent emerging infectious diseases.

Antibodies for HIV prevention

IAVI and partners are applying their expertise gained from HIV vaccine research to produce what could be a breakthrough in the fight against HIV/AIDS: an injection of bnAbs to prevent HIV infection.

MTBVAC: the only live-attenuated Mtb vaccine in development

IAVI is partnering with the Spanish biopharmaceutical company Biofabri in the advanced clinical development of the MTBVAC vaccine candidate to see if it prevents TB disease in infants, adolescents, and adults. MTBVAC is the only live, attenuated vaccine candidate derived from M.tb.

IAVI Design and Development Lab

The IAVI Vaccine Design and Development Lab generates and develops innovative HIV and emerging infectious diseases vaccine candidates to address global public health needs.

ADVANCE

ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic) is a 5-year cooperative agreement extended through June 2026 with the U.S. Agency for International Development (USAID), through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).

Most recent

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

About IAVI’s Lassa virus vaccine program

IAVI and our partners are developing a single-dose vaccine candidate for protection against Lassa virus (LASV). No vaccine is yet approved to prevent Lassa fever, the illness caused by LASV.

Read more

About IAVI’s Marburg virus vaccine program

IAVI is developing a vaccine candidate for protection against Marburg virus (MARV), a deadly pathogen and potential bioweapon that repeatedly causes severe outbreaks.

Read more

About IAVI’s Sudan virus vaccine program

IAVI is developing a vaccine candidate for protection against Sudan virus (SUDV) and has contributed to outbreak responses in sub-Saharan Africa. 

Read more

IAVI 2024 Annual Report

An overview of the progress IAVI and partners made in 2024 toward our pursuit to translate scientific discoveries into affordable, globally accessible public health solutions.

Read more

Workshop report: Financing TB vaccines R&D – African priorities, needs and stakeholder perspectives

In this report, we synthesize key insights and recommendations across three thematic areas that emerged during the workshop, convened on 19 June 2025 at the 12th EDCTP Forum in Kigali, Rwanda. The workshop brought together 20 experts from diverse global and regional institutions to explore the priorities, needs, and perspectives of African stakeholders to enhance support of TB vaccine research and development R&D.

Read more

Workshop report: Towards a proposal for a novel TB vaccine R&D financing initiative

This report captures the key insights from a roundtable discussion, convened on 14 October 2024 at the World Health Assembly in Berlin, Germany, focused on innovative financing mechanisms to support the late-stage development of tuberculosis (TB) vaccines. The session aimed to harness expert perspectives on potential financing strategies and criteria that could be applied to TB vaccine development, with three thematic recommendations emerging.

Read more

Technical brief: Towards a proposal for a novel TB vaccine R&D financing initiative

This brief outlines key considerations and tentative recommendations towards a new financing initiative for TB vaccines R&D, with a focus on late-stage candidates. It is designed to provide background information to help stimulate debate during the workshop series on late-stage TB vaccine R&D financing R&D. The contents of this paper and the outputs of the workshop series, which includes engagement with a range of key stakeholders, will inform the development of a validated proposal for late-stage TB vaccine R&D financing.

Read more

Advancing access to monoclonal antibodies in Africa: setting priorities, assessing feasibility, and enabling R&D and manufacturing

This meeting report synthesizes key learnings and recommendations from a 2023 workshop on advancing access to monoclonal antibodies (mAbs) in Africa conducted jointly by the Africa Centres for Disease Control and Prevention and IAVI, with the support of Wellcome. The workshop was held as an official side meeting of the 3rd International Conference of Public Health in Africa.

Read more